Featured Research

from universities, journals, and other organizations

Using biologic agents to induce remission for Crohn's disease

Date:
December 17, 2013
Source:
American Gastroenterological Association
Summary:
The anti-TNF- biologic agents, such as infliximab or adalimumab, are recommended to induce remission in patients with moderately severe Crohn's disease , according to a new guideline from the American Gastroenterological Association.

The anti-TNF-α biologic agents, such as infliximab or adalimumab, are recommended to induce remission in patients with moderately severe Crohn's disease, according to a new guideline from the American Gastroenterological Association (AGA). Additionally, the guidelines recommend against using thiopurines or methotrexate alone to induce remission in these patients. The new guideline and accompanying technical review have been published in Gastroenterology, the official journal of the AGA Institute. The AGA Clinical Decision Support Tool, based on the guideline, can be reviewed at http://gastro.org/crohnsdecisiontool.

"Crohn's disease is a lifelong, relapsing disorder that can damage the bowel and lead to multiple abdominal operations over time. Deciding which medications are the best is a common dilemma for gastroenterologists and the Crohn's patients we treat. The disease can be disabling, but the drugs to control the disease can be toxic too and they can be costly. Balancing the benefits and the risks of the drugs and determining which medicines are most likely to keep the patient healthy is critical," according to Jonathan P. Terdiman, MD, lead author of the guidelines, and Chief of the Gastroenterology Service at the University of California, San Francisco Medical Center. "The new AGA guideline and clinical decision support tool will ease the decision process by providing transparent and actionable recommendations."

Crohn's disease is a chronic inflammatory bowel disease that causes significant morbidity and represents a considerable burden to society. It is estimated that 300,000 to 500,000 Americans suffer from Crohn's disease, costing the health-care system between $2.5 and $4 billion per year.

These guidelines are the first to make medication recommendations based on methodology that includes review of risks and benefits, patient preferences, and the quality of clinical evidence.

For the induction of remission, the guidelines recommend:

  • Using anti-TNF-α drugs to induce remission in patients with moderately severe Crohn's disease (strong recommendation, moderate-quality evidence).
  • Using anti-TNF-α monotherapy over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn's disease (strong recommendation, moderate-quality evidence).
  • Using anti-TNF-α drugs in combination with thiopurines over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn's disease (strong recommendation, high-quality evidence).

For maintenance of remission, the guidelines recommend:

  1. Using thiopurines over no immunomodulator therapy to maintain a steroid-induced remission in patients with Crohn's disease (strong recommendation, moderate-quality evidence).
  2. Using anti-TNF-α drugs over no anti-TNF-α drugs to maintain a steroid or anti-TNF-α drug-induced remission in patients with Crohn's disease (strong recommendation, high-quality evidence).

Read the "American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti-TNF-a Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease" to review all of the treatment recommendations, available here: http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508513015217.pdf


Story Source:

The above story is based on materials provided by American Gastroenterological Association. Note: Materials may be edited for content and length.


Journal References:

  1. Terdiman J P et al. American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn’s Disease. Gastroenterology, 2013;145:1459-1463
  2. Dassopoulos T et al. American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn’s Disease. Gastroenterology, 2013;145:1464-1478

Cite This Page:

American Gastroenterological Association. "Using biologic agents to induce remission for Crohn's disease." ScienceDaily. ScienceDaily, 17 December 2013. <www.sciencedaily.com/releases/2013/12/131217104413.htm>.
American Gastroenterological Association. (2013, December 17). Using biologic agents to induce remission for Crohn's disease. ScienceDaily. Retrieved April 17, 2014 from www.sciencedaily.com/releases/2013/12/131217104413.htm
American Gastroenterological Association. "Using biologic agents to induce remission for Crohn's disease." ScienceDaily. www.sciencedaily.com/releases/2013/12/131217104413.htm (accessed April 17, 2014).

Share This



More Health & Medicine News

Thursday, April 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Thousands Of Vials Of SARS Virus Go Missing

Thousands Of Vials Of SARS Virus Go Missing

Newsy (Apr. 16, 2014) A research institute in Paris somehow misplaced more than 2,000 vials of the deadly SARS virus. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins